文献速递脊柱关节炎其他结缔组织病

银屑病关节炎与单纯银屑病患者的内脏脂肪及其与代谢和心血管风险的关系

Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

本研究为病例对照研究,比较52例银屑病关节炎(PsA)和52例单纯银屑病(PsO)患者与按年龄、性别、BMI类别1:1匹配的对照。DXA显示PsO患者腹部和内脏脂肪显著高于对照,而PsA患者与对照无差异;校正后PsO内脏脂肪高于PsA和对照。PsO内脏脂肪与SCORE心血管风险强相关(r=0.61)。

要点

  • 单纯银屑病患者内脏脂肪较匹配对照显著增加,而PsA患者无此差异。
  • 校正年龄、性别和BMI后,PsO内脏脂肪高于PsA(P=0.0004)和对照(P=0.0013)。
  • PsO患者内脏脂肪与SCORE心血管风险强相关(r=0.61)。

核心结论

  • 单纯银屑病患者内脏脂肪堆积较PsA更明显,内脏肥胖可能是PsO更突出的问题。

研究设计与样本

  • 法国Besançon开展的病例对照研究(ADIPSO,NCT02849795),纳入52例PsA和52例PsO患者,各按年龄、性别、BMI类别1:1匹配对照。
  • 采用DXA评估体成分和脂肪分布(腹部脂肪和内脏脂肪),并检测代谢参数、脂肪因子和SCORE心血管风险。

主要发现

  • PsO患者腹部脂肪和内脏脂肪显著高于其对照,而PsA患者与对照间无差异。
  • 多因素校正年龄、性别和BMI后,PsO患者内脏脂肪高于PsA患者(P=0.0004)和全部对照(P=0.0013)。
  • PsA和PsO两组胰岛素水平及HOMA-IR均升高;PsO患者高分子量/总脂联素比值降低;两组RBP4均显著升高。
  • PsO患者内脏脂肪与SCORE强相关(r=0.61)。

临床怎么用

  • 对单纯银屑病患者应关注内脏脂肪堆积及代谢和心血管风险评估。
  • PsA患者同样存在胰岛素抵抗和RBP4升高,需管理代谢共病。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fat mass distribution, especially in the abdominal visceral region, has been rarely evaluated in patients with PsA or psoriasis (PsO). METHODS: Patients with PsA and patients with PsO alone were evaluated and compared with control subjects (1:1 ratio in each patient group) matched for age, sex and BMI category. Body composition and fat distribution (android and visceral fat) were evaluated by DXA. Anthropometric measurements, disease activity and the systematic coronary risk evaluation (SCORE) cardiovascular risk were assessed. Metabolic parameters (insulin, homeostasis model assessment for insulin resistance), serum adipokines [total and high-molecular-weight adiponectin, leptin, resistin and retinol-binding protein-4 (RBP4)] were measured. RESULTS: Data for 52 patients with PsA and 52 patients with PsO and their respective paired controls were analysed. Android fat and visceral fat were found to be significantly higher in patients with PsO compared with their controls, while these measurements did not differ between patients with PsA and their controls. By multivariate analysis, after adjusting for age, sex and BMI, visceral fat was higher in PsO patients compared with PsA patients (P = 0.0004) and the whole group of controls (P = 0.0013). Insulin levels and HOMA-IR were increased in both PsA and PsO groups. High-molecular-weight/total adiponectin ratio was decreased in patients with PsO. RBP4 was significantly higher in both PsA and PsO patients. In patients with PsO, visceral fat strongly correlated with SCORE (r = 0.61). CONCLUSION: Visceral fat accumulates more in PsO alone than in PsA. Visceral adiposity may be a more pressing concern in PsO relative to PsA. TRIAL REGISTRATION: The ADIPSO study (Évaluation du tissu ADIpeux et des adipokines dans le PSOriasis et le rhumatisme psoriasique et analyse de ses relations avec le risque cardiovasculaire) is a case-control study conducted in Besançon, France, and is registered on ClinicalTrials.gov under the number NCT02849795.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Toussirot E, Aubin F, Desmarets M, et al. Visceral adiposity in patients with psoriatic arthritis and psoriasis alone and its relationship with metabolic and cardiovascular risk. Rheumatology (Oxford). 2021. PMID: 33232483. doi:10.1093/rheumatology/keaa720

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。